Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID : A compendium statement
PM&R · 2025-06 · 17 (6) · 684-708
DOI: 10.1002/pmrj.13397 ↗Kurz gefasst
Fachartikel in der Zeitschrift PM&R, online erschienen am 22.04.2025. Verfasst von Abby L Cheng und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Musculoskeletal Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Washington University in St. Louis, St. Louis, M…. Hauptthemen laut MEDLINE: COVID-19, Practice Guidelines as Topic, Patient Care Team. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS, NHLBI NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
Background
In 2021, the American Academy of Physical Medicine and Rehabilitation established the Multi‐Disciplinary Post‐Acute Sequelae of SARS‐CoV‐2 Infection Collaborative to provide guidance from established Long COVID clinics for the evaluation and management of Long COVID. The collaborative previously published eight Long COVID consensus guidance statements using a primarily symptom‐based approach. However, Long COVID symptoms most often do not occur in isolation.
Aims
This compendium aims to equip clinicians with an efficient, up‐to‐date clinical resource for evaluating and managing adults experiencing Long COVID symptoms. The primary intended audience includes physiatrists, primary care physicians, and other clinicians who provide first‐line assessment and management of Long COVID symptoms, especially in settings where subspecialty care is not readily available. This compendium provides a holistic framework for assessment and management, symptom‐specific considerations, and updates on prevalence, health equity, disability considerations, pathophysiology, and emerging evidence regarding treatments under investigation. Because Long COVID closely resembles other infection‐associated chronic conditions (IACCs) such as myalgic encephalomyelitis/chronic fatigue syndrome, the guidance in this compendium may also be helpful for clinicians managing these related conditions.
Methods
Guidance in this compendium was developed by the collaborative's established modified Delphi approach. The collaborative is a multidisciplinary group whose members include physiatrists, primary care physicians, pulmonologists, cardiologists, psychiatrists, neuropsychologists, neurologists, occupational therapists, physical therapists, speech and language pathologists, patients, and government representatives. Over 40 Long COVID centers are represented in the collaborative.
Results
Long COVID is defined by the National Academies of Sciences, Engineering, and Medicine as “an IACC that occurs after SARS‐CoV‐2 infection and is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems.” The current global prevalence of Long COVID is estimated to be 6%. Higher prevalence has been identified among female gender, certain racial and ethnic groups, and individuals who live in nonurban areas. However, anyone can develop Long COVID after being infected with the SARS‐CoV‐2 virus. Long COVID can present as a wide variety of symptom clusters. The most common symptoms include exaggerated fatigue and diminished energy windows, postexertional malaise (PEM)/postexertional symptom exacerbation (PESE), cognitive impairment (brain fog), dysautonomia, pain/myalgias, and smell and taste alterations. Holistic assessment should include a traditional history, physical examination, and additional diagnostic testing, as indicated. A positive COVID‐19 test during acute SARS‐CoV‐2 infection is not required to diagnose Long COVID, and currently, there is no single laboratory finding that is definitively diagnostic for confirming or ruling out the diagnosis of Long COVID. A basic laboratory assessment is recommended for all patients with possible Long COVID, and consideration for additional labs and diagnostic procedures is guided by the patient's specific symptoms. Current management strategies focus on symptom‐based supportive care. Critical considerations include energy conservation strategies and addressing comorbidities and modifiable risk factors. Additionally, (1) it is essential to validate the patient's experience and provide reassurance that their symptoms are being taken seriously because many patients have had their symptoms dismissed by loved ones and clinicians; (2) physical activity recommendations must be carefully tailored to the patient's current activity tolerance because overly intense activity can trigger PEM/PESE and worsened muscle damage; and (3) treatment recommendations should be delivered with humility because there are many persistent unknowns related to Long COVID. To date, there are limited data to guide medication management specifically in the context of Long COVID. As such, medication use generally follows standard practice regarding indications and dosing, with extra attention to prioritize (1) patient preference via shared decision‐making and (2) cautious use of medications that may improve some symptoms (eg, cognitive/attention impairment) but may worsen other symptoms (eg, PEM/PESE). Numerous clinical trials are investigating additional treatments. The return‐to‐work process for individuals with Long COVID can be challenging because symptoms can fluctuate, vary in nature, affect multiple functional areas (eg, physical and cognitive), and often manifest as an “invisible disability” that may not be readily acknowledged by employers or coworkers. Clinicians can help patients return to work by identifying suitable workplace accommodations and resources, providing necessary documentation, and recommending occupational or vocational therapy when needed. If these efforts are unsuccessful and work significantly worsens Long COVID symptoms or impedes recovery, applying for disability may be warranted. Long COVID is recognized as a potential disability under the Americans with Disabilities Act.
Conclusion
To contribute to the overall health and well‐being for all patients, Long COVID care should be delivered in a holistic manner that acknowledges challenges faced by the patient and uncertainties in the field. For more detailed information on assessment and management of specific Long COVID symptoms, readers can reference the collaborative's symptom‐specific consensus guidance statements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Musculoskeletal Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Washington University in St. Louis, St. Louis, Missouri, USA.
- Department of Family Medicine, Oregon Health & Sciences University, Portland, Oregon, USA.
- Department of Physical Medicine and Rehabilitation, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Department of Psychiatry and Neurology, Oregon Health and Science University, Portland, Oregon, USA.
- Department of Pediatrics, Division of Adolescent Medicine, Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Physical Medicine and Rehabilitation, UNC-Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Abby L Cheng, John M Baratta, Talya K Fleming, Monica Verduzco-Gutierrez, Leslie Rydberg, Julie K Silver
Förderung
- AHRQ HHS
- NHLBI NIH HHS
- NIDA NIH HHS
- NIMH NIH HHS
- BLRD VA
Zitieren
APA
Cheng, A. L., Herman, E., Abramoff, B., Anderson, J. R., Azola, A., Baratta, J. M., Bartels, M. N., Bhavaraju-Sanka, R., Blitshteyn, S., Fine, J. S., Fleming, T. K., Verduzco-Gutierrez, M., Herrera, J. E., Karnik, R., Kurylo, M., Longo, M. T., McCauley, M. D., Melamed, E., Miglis, M. G., …, & Niehaus, W. N. (2025). Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID : A compendium statement. PM&R, 17(6), 684-708. https://doi.org/10.1002/pmrj.13397
Vancouver
Cheng AL, Herman E, Abramoff B, Anderson JR, Azola A, Baratta JM, et al. Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID : A compendium statement. PM&R. 2025;17(6):684-708. doi:10.1002/pmrj.13397
BibTeX
@article{Cheng2025,
author = {Cheng, Abby L and Herman, Eric and Abramoff, Benjamin and Anderson, Jordan R and Azola, Alba and Baratta, John M and Bartels, Matthew N and Bhavaraju-Sanka, Ratna and Blitshteyn, Svetlana and Fine, Jeffrey S and Fleming, Talya K and Verduzco-Gutierrez, Monica and Herrera, Joseph E and Karnik, Rasika and Kurylo, Monica and Longo, Michele T and McCauley, Mark D and Melamed, Esther and Miglis, Mitchell G and Neal, Jacqueline D and Oleson, Christina V and Putrino, David and Rydberg, Leslie and Silver, Julie K and Terzic, Carmen M and Whiteson, Jonathan H and Niehaus, William N},
title = {Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID : A compendium statement},
journal = {PM&R},
year = {2025},
volume = {17},
number = {6},
pages = {684--708},
doi = {10.1002/pmrj.13397}
}
EUVIMED